

Cysteine);

osteopontin;
collagens, Type I and Type II;
von Willebrand Factor;
bone sialoprotein;
thrombospondin;
osteocalcin;
cytomodulin;
bone morphogenetic proteins (BMPs);
tenascins;
fibrinolysis inhibiting factor;
growth factors, Platelet Derived Growth Factors (PDGF),
Insulin-Like Growth Factors (IGFs); and
antibodies to cell surface components, β -1; integrin
antibody.--

REMARKS

The enclosed sequence listing and amendments to the specification and claims do not go beyond the disclosure in the application as filed. Further, the information recorded in the machine readable form (item (3) above) is identical to the written sequence listing (item (2) above).

Applicant now awaits the first office action on the merits of the application. However, if the Examiner requires any further information or changes with respect to the sequence listings, he/she is requested to contact the undersigned at (818)710-2788.

Please acknowledge safe receipt hereof by stamping and returning the enclosed postcard.

Respectfully submitted,

September 27, 2002



Colin P. Abrahams
Attorney for the Applicant
Registration No. 32,393

5850 Canoga Avenue, Suite 400,
Woodland Hills, California 91367.
Telephone: (818)710-2788
Fax: (818)710-2798

Enclosed: A copy of the "Notice to Comply...";
Sequence listing in written form;
Computer readable form (CRF) of the "Sequence Listing";
Revised claim pages 36 to 39a;
Petition for extension;
Check for extension; and
Return postcard.

Certificate of Mailing (37 CFR 1.8):

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on September 30, 2002.



Colin P. Abrahams